These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 793268)

  • 21. [Treatment of raynaud's disease and phenomenon with intraarterial reserpine (author's transl)].
    González Folch M; Saffie F
    Rev Med Chil; 1976 Jan; 104(1):21-4. PubMed ID: 788084
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical trial of a new vasoactive drug F.I. 6714 administered intra-arterially in peripheral vascular diseases].
    Masini G
    Minerva Cardioangiol; 1975 Feb; 23(2):120-5. PubMed ID: 1095956
    [No Abstract]   [Full Text] [Related]  

  • 23. [Raynaud's disease and phenomenon].
    Vilardell Tarrés M
    Med Clin (Barc); 1983 Dec; 81(18):808-10. PubMed ID: 6656450
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of Raynaud's syndrome].
    Cloarec M; Cristol R; Graisely B
    Sem Hop Ther; 1977; 53(7-8):357-62. PubMed ID: 594750
    [No Abstract]   [Full Text] [Related]  

  • 25. [Management of Raynaud's phenomenon].
    Boccalon H; Monin A; Reggy M
    Soins Cardiol; 1986 Apr; (38):27-9. PubMed ID: 3637023
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
    Kamata Y; Kamimura T; Iwamoto M; Minota S
    Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
    [No Abstract]   [Full Text] [Related]  

  • 28. Raynaud's phenomenon.
    O'connor CM
    J Vasc Nurs; 2001 Sep; 19(3):87-92; quiz 93-4. PubMed ID: 11533581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of patients with secondary Raynaud's syndrome.
    Ehrly AM
    Acta Chir Scand Suppl; 1976; 465():92-5. PubMed ID: 1069443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Raynaud's phenomenon: diagnostic and therapeutic aspects].
    Soro P; Occhioni G; Spissu M; Trignano M; Dettori G; Bacciu PP; Biglioli P
    Chir Ital; 1981 Jun; 33(3):647-60. PubMed ID: 7307205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical treatment of peripheral vascular disease: are there new perspectives?
    Smit AJ
    Vasa Suppl; 1992; 34():20-4. PubMed ID: 1529413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?
    Hughes M; Khanna D; Pauling JD
    Rheumatology (Oxford); 2020 Mar; 59(3):464-466. PubMed ID: 31670800
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of angiodystrophic skin diseases with ginkgo-biloba].
    Nazzaro P; Di Carlo A
    Minerva Med; 1973 Nov; 64(79 Suppl):4198-200. PubMed ID: 4592297
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical inquiries. What is the evaluation and treatment strategy for Raynaud's phenomenon?
    Tagliarino H; Purdon M; Jamieson B; Hoekzema G
    J Fam Pract; 2005 Jun; 54(6):553-5. PubMed ID: 15939010
    [No Abstract]   [Full Text] [Related]  

  • 35. [Thermography in evaluating therapy in Raynaud's disease].
    Litmanovitch J; Shilo R; Chayen M
    Harefuah; 1972 Jun; 82(11):503-6. PubMed ID: 5068900
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of functional changes in arteriosclerotic chronic obliterating peripheral arterial diseases (COPA) and Buerger's and Raynaud's diseases with pharmacological sympathicolysis, with or without indirect surgical treatment].
    Bagliani A; Borri P; Taborelli R
    Minerva Cardioangiol; 1973 Jun; 21(6):439-52. PubMed ID: 4720185
    [No Abstract]   [Full Text] [Related]  

  • 37. Vasodilator refractoriness in Raynaud's syndrome.
    Sarkany I; Tan OT; Gaylarde PM
    Clin Exp Dermatol; 1982 Nov; 7(6):679-80. PubMed ID: 7151321
    [No Abstract]   [Full Text] [Related]  

  • 38. Reserpine in Raynaud's phenomenon.
    Lancet; 1970 Aug; 2(7670):454. PubMed ID: 4195127
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of Raynaud's phenomenon: new insights and developments.
    Herrick AL
    Curr Rheumatol Rep; 2003 Apr; 5(2):168-74. PubMed ID: 12628049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study of the plethysmographic amplification factor during vasodilator treatment. Healthy subject versus primary Raynaud phenomenon].
    Lasfargues G; Royere D; Perrotin D; Titon JP; Soutif D; Guilmot JL
    J Mal Vasc; 1987; 12(4):319-22. PubMed ID: 3694055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.